BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System, ...

(RTTNews) - Boston Scientific Corp. (BSX) announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System, the first modular cardiac rhythm management ...

Please provide your email address to receive an email when new articles are posted on . A single burst of antitachycardia pacing (ATP) reduced risk for shocks in patients with an implantable ...

Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...